By Scientia Professor Vlado Perkovic

Book Chapters

Rahimi K; Perkovic V, 2018, 'Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialists' Collaboration', in Hypertension: A Companion to Braunwald's Heart Disease, pp. 433 - 441, http://dx.doi.org/10.1016/B978-0-323-42973-3.00047-0

Rahimi K; Perkovic V, 2018, '47 Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialists’ Collaboration', in Hypertension: A Companion to Braunwald's Heart Disease, Elsevier, pp. 433 - 441, http://dx.doi.org/10.1016/b978-0-323-42973-3.00047-0

Jun M; Perkovic V, 2015, 'Fibrates: risk-benefits and role in treating dyslipidemias', in Dyslipidemias Pathophysiology, Evaluation and Management, Humana Press

Wang AY; Jardine M; Perkovic V, 2014, 'Kidney Disease in Diabetes', in Managing Cardiovascular Complications in Diabetes, pp. 58 - 86, http://dx.doi.org/10.1002/9781118337967.ch3

Wang Y; Perkovic V; Jardine M, 2014, 'kidney disease in diabetes', in Managing Cardiovascular Complications in Diabetes, John Wiley & Sons

Wang Y; Ivany JN; Perkovic V; Gallagher MP; Jardine MJ, 2012, 'Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease', in Wang Y (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd009631

Gangadharan Komala M; Pianta TJ; Jardine MJ; Webster AC; Perkovic V, 2011, 'Interventions for preventing intradialytic hypotension in haemodialysis patients', in Gangadharan Komala M (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd009459

Jun M; Perkovic V; Cass A, 2011, 'Intensive glycemic control and renal outcome', in Diabetes and the Kidney, Karger Medical and Scientific Publishers

Razavian M; Di Micco L; Palmer SC; Craig JC; Perkovic V; Zoungas S; Webster AC; Jardine MJ; Strippoli GFM, 2010, 'Antiplatelet agents for chronic kidney disease', in Palmer SC (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd008834

Badve SV; Beller E; Cass A; Francis DP; Hawley C; Macdougall IC; Perkovic V; Johnson DW, 2010, 'Interventions for erythropoietin-resistant anaemia in dialysis patients', in Badve SV (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd006861.pub2

Perkovic V; Venkataraman V; Cooper B; Zoungas S; Webster AC, 2009, 'Antioxidants for chronic kidney disease', in Perkovic V (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd008176

Gallagher M; Perkovic V; Jardine M; Cass A, 2009, 'Lipid lowering in chronic kidney disease', in Therapeutic Strategies in Lipid Disorders

Perkovic V; Craig JC; Masterson R; Webster A, 2004, 'HMG CoA reductase inhibitors (statins) for kidney transplant recipients', in Perkovic V (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd005019

Journal articles

Mann JFE; Rossing P; Bakris G; Belmar N; Bosch-Traberg H; Busch R; Charytan DM; Hadjadj S; Gillard P; Górriz JL; Idorn T; Ji L; Mahaffey KW; Perkovic V; Rasmussen S; Schmieder RE; Pratley RE; Tuttle KR, 2024, 'Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.', Nat Med, http://dx.doi.org/10.1038/s41591-024-03133-0

Heerspink HJL; Agarwal R; Bakris GL; Cherney DZI; Lam CSP; Neuen BL; Sarafidis PA; Tuttle KR; Wanner C; Brinker MD; Dizayee S; Kolkhof P; Schloemer P; Vesterinen P; Perkovic V; FIND-CKD investigators , 2024, 'Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.', Nephrol Dial Transplant, http://dx.doi.org/10.1093/ndt/gfae132

Patel SM; Kang YM; Im KA; Neuen BL; Anker SD; Bhatt DL; Butler J; Cherney DZI; Claggett BL; Fletcher RA; Herrington WG; Inzucchi SE; Jardine MJ; Mahaffey KW; McGuire DK; McMurray JJV; Neal B; Packer M; Perkovic V; Solomon SD; Staplin N; Vaduganathan M; Wanner C; Wheeler DC; Zannad F; Zhao Y; Heerspink HJL; Sabatine MS; Wiviott SD, 2024, 'Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis', Circulation, 149, pp. 1789 - 1801, http://dx.doi.org/10.1161/CIRCULATIONAHA.124.069568

Perkovic V; Tuttle KR; Rossing P; Mahaffey KW; Mann JFE; Bakris G; Baeres FMM; Idorn T; Bosch-Traberg H; Lausvig NL; Pratley R; FLOW Trial Committees and Investigators , 2024, 'Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.', N Engl J Med, http://dx.doi.org/10.1056/NEJMoa2403347

Perkovic V; Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Renfurm R; Rizk DV, 2024, '#456 Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study', Nephrology Dialysis Transplantation, 39, http://dx.doi.org/10.1093/ndt/gfae069.141

Neuen BL; Claggett BL; Perkovic V; Jardine M; Heerspink HJL; Mahaffey KW; McMurray JJV; Solomon SD; Vaduganathan M, 2024, 'Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From Four Large-Scale Placebo-Controlled Outcome Trials.', Circulation, http://dx.doi.org/10.1161/CIRCULATIONAHA.124.069382

Fussner LA; Flores-Suárez LF; Cartin-Ceba R; Specks U; Cox PG; Jayne DRW; Merkel PA; Walsh M; Paizis K; Walters G; Jardine M; Milton C; Ibraham A; Siva B; Desmond M; Perkovic V; Kurtkoti J; Vilayur E; Cass A; Summers S; Brown F; Ryan J; Kerr P; Noble E; Luxton G; Mudge DW; Hawley C; Johnson DW; Peh CA; Faull RJ; Ranganathan D; Jeffs L; Nicholls K; Hughes P; Cooper B; Boudville N; Ford S; Langham R; Reidlinger D; Morrish A; Badve SV; Pascoe E; Paul-Brent PA; Robison L; Valks A; Blockmans D; Henckaerts L; Sprangers B; Suri R; Brachemi S; Clark W; Garg A; Carette S; Pagnoux C; Reich H; Barth D; Khalidi N; Cox G; Mazzetti A; Robins D; Wald R; Perl J; Pavenski K; Dacouris N; Levin A; Copland M; Fairhead T; Pannu N; Qarni MU; Habib S; Girard L; Manns B; Tesar V; Hruskova Z; Chocova Z; Povlsen J; Gregersen J; Ivarsen P; Birn H; Krarup E; Pedersen EB; Thomsen I; Bech JN; Szpirt W; Egfjord M; Mesbah R; Bataille P; Rey I; Chantrel F; Vanhille P; Quémeneur T; Carron PL; Zaoui P; de Moreuil C; Gosselin M; Delluc A; Hanrotel-Saliou C; Le Jeune M; Ficheux M; Aniort J, 2024, 'Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Results of an International Randomized Controlled Trial (PEXIVAS)', American Journal of Respiratory and Critical Care Medicine, 209, pp. 1141 - 1151, http://dx.doi.org/10.1164/rccm.202308-1426OC

Heerspink HJL; Stack AG; Terkeltaub R; Jongs N; Inker LA; Bjursell M; Maklad N; Perl S; Eklund O; Rikte T; Sjöström CD; Perkovic V; Chmelickova H; Lukac M; Bucek P; Drasnar T; Dussol B; Guerrot D; Legrand E; Boffa JJ; Halimi JM; Zaoui P; Letoha A; Hajdu C; Pall D; Peterfai E; Csécsei G; Bezzegh K; Deak L; Konyves L; Zsom M; Danos P; Vangel S; Vasas S; Oroszlan T; Zilahi Z; Leiba A; Grossman A; Leibowitz A; Itzhak B; Daoud D; Farber E; Adawi F; Nakhoul FM; Chernin G; Kenis I; Wainstein J; Zeller L; Elias M; Atar S; Frajewicki V; Yagil Y; Armaly ZA; Esposito C; Viazzi F; Gambaro G; Piatti P; Bonadonna RC; Arias Delgadillo CR; Flores FJ; Aguilera Real ME; Fajardo-Campos P; Violante Ortiz RM; Luna Ceballos RI; Duran-Barragan S; Zytkiewicz-Jaruga D; Krzyzagorska E; Skokowska E; Klodawska K; Mordaka R; Mazur S; Stasinska T; Sulowicz W; Constantin C; Negru D; Paveliu FS; Negrisanu GD; Szilagyi I; Busegeanu MMG; Pena MC; Avram RI; Ardelean SL; Ilavska A; Dzupina A; Oroszova A; Kolesarova E; Obetkova I; Smatanova I; Babikova J; Fulop P; Haffner R; Rayner BL; Kruger DS; Urbach DV; Mitha E; Vally Mahomed Latiff GH; Makan H; Du Plessis H; Jurgens JC; Reddy J, 2024, 'Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial', Journal of the American Society of Nephrology, 35, pp. 594 - 606, http://dx.doi.org/10.1681/ASN.0000000000000326

Cunningham JW; Claggett BL; Lopes RD; McMurray JJV; Perkovic V; Carroll K; Hiemstra T; Khavandi K; Lukas MA; Ranganathan P; Shannon J; Van Adelsberg J; Singh AK; Solomon SD, 2024, 'Daprodustat and Heart Failure in CKD', Journal of the American Society of Nephrology, 35, pp. 607 - 617, http://dx.doi.org/10.1681/ASN.0000000000000321

Fletcher RA; Herrington WG; Agarwal R; Mayne KJ; Arnott C; Jardine MJ; Mahaffey KW; Perkovic V; Staplin N; Wheeler DC; Chertow GM; Heerspink HJL; Neuen BL, 2024, 'Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials.', Clin J Am Soc Nephrol, http://dx.doi.org/10.2215/CJN.0000000000000470

Trachtman H; Radhakrishnan J; Rheault MN; Alpers CE; Barratt J; Heerspink HJL; Noronha IL; Perkovic V; Rovin B; Trimarchi H; Wong MG; Mercer A; Inrig J; Rote W; Murphy E; Bedard PW; Roth S; Bieler S; Komers R, 2024, 'Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study', Kidney International Reports, 9, pp. 1020 - 1030, http://dx.doi.org/10.1016/j.ekir.2024.01.032

Kim D; Perkovic V; Kotwal S, 2024, 'Barriers to Care: New Medications and CKD', Kidney International Reports, 9, pp. 504 - 507, http://dx.doi.org/10.1016/j.ekir.2023.12.012

Tobe SW; Mavrakanas TA; Bajaj HS; Levin A; Tangri N; Slee A; Neuen BL; Perkovic V; Mahaffey KW; Rapattoni W; Ang FG, 2024, 'Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials', Diabetes Care, 47, pp. 501 - 507, http://dx.doi.org/10.2337/dc23-1450

Ha JT; Freedman SB; Kelly DM; Neuen BL; Perkovic V; Jun M; Badve SV, 2024, 'Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', American Journal of Kidney Diseases, 83, pp. 350 - 359.e1, http://dx.doi.org/10.1053/j.ajkd.2023.07.023

Cheung CK; Barratt J; Carroll K; Lafayette RA; Liew A; Suzuki Y; Tesař V; Trimarchi H; Wong MG; Zhang H; Perkovic V; Rizk DV, 2024, 'Targeting APRIL in the Treatment of IgA Nephropathy', Clinical Journal of the American Society of Nephrology, 19, pp. 394 - 398, http://dx.doi.org/10.2215/CJN.0000000000000338

Tangri N; Mathur VS; Bushinsky DA; Klaerner G; Li E; Parsell D; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Perkovic V; Inker LA, 2024, 'VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis', Journal of the American Society of Nephrology, 35, pp. 311 - 320, http://dx.doi.org/10.1681/ASN.0000000000000292

Marx N; Kolkailah AA; Rosenstock J; Johansen OE; Cooper ME; Alexander JH; Toto RD; Wanner C; Espeland MA; Mattheus M; Schnaidt S; Perkovic V; Gollop ND; McGuire DK, 2024, 'Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin A Secondary Analysis of Randomized Clinical Trials', JAMA Cardiology, 9, pp. 134 - 143, http://dx.doi.org/10.1001/jamacardio.2023.4602

Neuen BL; Heerspink HJL; Vart P; Claggett BL; Fletcher RA; Arnott C; de Oliveira Costa J; Falster MO; Pearson SA; Mahaffey KW; Neal B; Agarwal R; Bakris G; Perkovic V; Solomon SD; Vaduganathan M, 2024, 'Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria', Circulation, 149, pp. 450 - 462, http://dx.doi.org/10.1161/CIRCULATIONAHA.123.067584

Sharma A; Razaghizad A; Joury A; Levin A; Bajaj HS; Mancini GBJ; Wong NC; Slee A; Ang FG; Rapattoni W; Neuen BL; Arnott C; Perkovic V; Mahaffey KW, 2024, 'Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial', Journal of the American Heart Association, 13, http://dx.doi.org/10.1161/JAHA.123.031586

Neuen BL; Jun M; Wick J; Kotwal S; Badve SV; Jardine MJ; Gallagher M; Chalmers J; Nallaiah K; Perkovic V; Peiris D; Rodgers A; Woodward M; Ronksley PE, 2024, 'Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data', The Lancet Regional Health - Western Pacific, 43, http://dx.doi.org/10.1016/j.lanwpc.2023.100988

Jun M; Wick J; Neuen BL; Kotwal S; Badve SV; Woodward M; Chalmers J; Peiris D; Rodgers A; Nallaiah K; Jardine MJ; Perkovic V; Gallagher M; Ronksley PE, 2024, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', Kidney International Reports, 9, pp. 312 - 322, http://dx.doi.org/10.1016/j.ekir.2023.11.022

Sharma A; Marques P; Neuen BL; Fletcher RA; Slee A; Rapattoni W; Ang FG; Arnott C; Levin A; Verma S; Perkovic V; Mahaffey KW, 2024, 'Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 26, pp. 758 - 762, http://dx.doi.org/10.1111/dom.15340

Kotwal S; Perkovic E; Perkovic V, 2024, 'Combination therapy with kidney protective therapies: Optimizing the benefits?', Current Opinion in Nephrology and Hypertension, 33, pp. 136 - 143, http://dx.doi.org/10.1097/MNH.0000000000000929

Pergola PE; Davidson M; Jensen C; Mohseni Zonoozi AA; Raj DS; Andreas Schytz P; Tuttle KR; Perkovic V, 2024, 'Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE)', Journal of the American Society of Nephrology, 35, pp. 74 - 84, http://dx.doi.org/10.1681/ASN.0000000000000245

Vaduganathan M; Cannon CP; Jardine MJ; Heerspink HJL; Arnott C; Neuen BL; Sarraju A; Gogate J; Seufert J; Neal B; Perkovic V; Mahaffey KW; Kosiborod MN, 2024, 'Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial', European Journal of Heart Failure, http://dx.doi.org/10.1002/ejhf.3292

Cardoza K; Kang A; Smyth B; Yi TW; Pollock C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Wheeler DC; Zhang H; Cannon CP; Perkovic V; Arnott C; Levin A; Mahaffey KW, 2024, 'Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial', Diabetes, Obesity and Metabolism, http://dx.doi.org/10.1111/dom.15685

Tangri N; Ferguson TW; Bamforth RJ; Leon SJ; Arnott C; Mahaffey KW; Kotwal S; Heerspink HJL; Perkovic V; Fletcher RA; Neuen BL, 2024, 'Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, http://dx.doi.org/10.1111/dom.15678

Zhang H; Rizk DV; Perkovic V; Maes B; Kashihara N; Rovin B; Trimarchi H; Sprangers B; Meier M; Kollins D; Papachristofi O; Milojevic J; Junge G; Nidamarthy PK; Charney A; Barratt J, 2024, 'Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy', Kidney International, 105, pp. 189 - 199, http://dx.doi.org/10.1016/j.kint.2023.09.027

Talbot B; Davies S; Burman J; Ritchie A; Snelling P; Lynch S; Park Y; Jones B; Garvey V; Jaure A; Jardine M; Perkovic V; Gallagher M; Brandwood A; Kaur N; Knight J, 2024, 'The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system', Peritoneal Dialysis International, http://dx.doi.org/10.1177/08968608231209850

Wong MG; Lv J; Neuen B; Monaghan H; Billot L; Perkovic V; Zhang H; Kim D, 2024, 'WCN24-1001 EFFECT OF CORTICOSTEROIDS ON KIDNEY AND SAFETY OUTCOMES IN IGA NEPHROPATHY ACROSS DIFFERENT LEVELS OF PROTEINURIA AND EGFR: A POST HOC ANALYSIS OF THE TESTING STUDY', Kidney International Reports, 9, pp. S151 - S151, http://dx.doi.org/10.1016/j.ekir.2024.02.310

Perkovic V; Kollins D; Renfurm R; Papachristofi O; Jacinto-Sanders S; Merkel T; Hach T; Rizk DV, 2024, 'WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY', Kidney International Reports, 9, pp. S506 - S506, http://dx.doi.org/10.1016/j.ekir.2024.02.1414

Trimarchi H; Barratt J; Radhakrishnan J; Rizk DV; Sorensen B; Leiske J; Khawaja Z; Campbell K; Perkovic V, 2024, 'WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY', Kidney International Reports, 9, pp. S177 - S177, http://dx.doi.org/10.1016/j.ekir.2024.02.362

Barratt J; Rovin B; Murphy E; Komers R; Trimarchi H; Perkovic V, 2024, 'WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL', Kidney International Reports, 9, pp. S505 - S506, http://dx.doi.org/10.1016/j.ekir.2024.02.1413

Heerspink HJL; Jongs N; Schloemer P; Little DJ; Brinker M; Tasto C; Karpefors M; Wheeler DC; Bakris G; Perkovic V; Nkulikiyinka R; Rossert J; Gasparyan SB, 2023, 'Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression', Journal of the American Society of Nephrology, 34, pp. 2025 - 2038, http://dx.doi.org/10.1681/ASN.0000000000000243

Fletcher RA; Jongs N; Chertow GM; McMurray JJV; Arnott C; Jardine MJ; Mahaffey KW; Perkovic V; Rockenschaub P; Rossing P; Correa-Rotter R; Toto RD; Vaduganathan M; Wheeler DC; Heerspink HJL; Neuen BL, 2023, 'Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials', Journal of the American Society of Nephrology, 34, pp. 1965 - 1975, http://dx.doi.org/10.1681/ASN.0000000000000248

Yu J; Sweeting AN; Gianacas C; Houston L; Lee V; Fletcher RA; Perkovic V; Li Q; Neuen BL; Berwanger O; Heerspink HJL; de Zeeuw D; Arnott C, 2023, 'The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 25, pp. 3724 - 3735, http://dx.doi.org/10.1111/dom.15267

Marx N; Deanfield JE; Gerward S; Hovingh GK; Plunde O; Pratley RE; Staerk-Ostergaard J; Perkovic V, 2023, 'Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide', European Heart Journal, 44, http://dx.doi.org/10.1093/eurheartj/ehad655.2751

Back to profile page